Market Comment

April 6, 2014

April 7, 2014

Notice that the stiffest tree is most easily cracked, while the bamboo or willow survives by bending with the wind.” — Bruce Lee

Friday’s Nasdaq downdraft got everyone’s attention, given its being the second-worst day in 22 months. Moreover, volume was the second-heaviest for a downday in nine months.

The Naz has shed 5.8% from its high four weeks ago to Friday’s low. This compares with the 1.8% loss in the S&P 500. As the below chart shows, the Nasdaq forms an expanding triangle, or megaphone pattern. This transpires as price prints a clear succession of lower highs and lower lows.

motm040614-nas

Friday’s move was led by the social medias, bios, and brokers. While the former two are in keeping with the four-week decline’s focus on high-expectation glamours, the brokers’ weakness says something about the bearish sentiment spreading to the broader market.

In particular, for decades the brokers have acted as a leading indicator of a primary market top. Seeing them lag the S&P 500, then, is a minus, though any signal they are giving is likely months away from coming to fruition. Recently, the group has been pressured by regulators looking into the practice of payment-for-order-flow, a significant contributor to revenue for some firms. The practice was discussed in Michael Lewis’ latest book on high-frequency trading (HFT).

Otherwise, the true health of a market can best be judged by the rally after a correction in the averages, especially its breadth, volume, and leadership. In light of the recent discrepancy in performance between small-capitalization and growth names vs large-capitalization issues, the next intermediate advance may show fewer stocks participating, i.e. deteriorating breadth. This is something we will be watching for.

The interesting aspect of this decline is the uniformity of losses in leading titles. Institutions are making very little distinction between senior glamours, such as Biogen (BIIB) and Priceline.com (PCLN), and junior glamours like Pandora (P) and Palo Alto Networks (PANW).

motm040614-biib

motm040614-panw

As mentioned a week ago, long-side pattern setups are fewer than at any time since ’12.

Among the names, Aercap Holdings (AER) was noted here in last week’s report: “An aggressive speculator could consider using the 43.69 high of 2/28 as an entrance pivot for a standard breakout.” The comment stands. This would assume general market tone had improved.

motm040614-aer

Auspex Pharmaceuticals (ASPX) is a development-stage biotech company that went public just two months ago and promptly tripled in its first six weeks. Yet its loss off the top is 16.9% vs. the 18.2% loss of the iShares Nasdaq Biotech ETF (IBB), when it might be expected to have dropped more. This is worth watching, but does not offer attractive entrance yet due to the sketchy market climate.

motm040614-aspx

Diamondback Energy (FANG) broke out of a five-week pattern a week ago, as was discussed in last week’s report. To its credit, it has held right around the lip despite the carnage in many shares. Its broad sector, energy, is the top-performer. As mentioned in the week-ago report, the breakout did not interest us, as the general market had shown enough deterioration to keep us away from most new commitments. But worth watching, as it shows it has leadership credentials in what is otherwise a very tough market.

motm040614-fang

Glycomimetics (GLYC) is an itty-bitty biotech, a teen-aged issue ($15.77) trading 188k shares a day on average ($2.97MM a day in average dollar volume). It came public 12 weeks ago and moved up 137% in nine weeks. Like ASPX above, it is a tertiary glamour that would be expected to fall more than the biotech index. Yet it has held up slightly better. Worth watching.

motm040614-glyc

Sierra Wireless (SWIR) is a cyclical company expected to grow earnings by 109%/73% in ‘14/’15. This is a 91 rs stock in a 94 rs group. The stock’s three-month pattern is being watched in the event the averages firm up, with the 24.84 point serving as a possible cheater entrance.

motm040614-swir

Staar Surgical (STAA) was noted here last week: “Price forms a two-week ledge pattern and is worth watching.” The comment stands. This is a thin issue ($5.2MM average volume per day) and hence contains higher risk. The 4/01 high of 19.28 serves as a potential entrance pivot.

motm040614-staa

Tesla Motors (TSLA) is worth watching to see if it can fill out its current basing pattern. Thursday’s high may possibly be used as a cheater entrance, though it is premature to plan for this at this time without knowing what market tone will be like. One of the few stocks to score triple-digit estimates for both ’14 and ’15.

motm040614-tsla

Zillow (Z) reported earnings in ’13 that were less than half what it made in ’12. In ’14 it is expected to make about a third what it made in ’13. Nevertheless, stock of the online provider of real estate data stays fairly buoyant as most analysts eye net of 69 cents a share in ’15, well above ‘14’s six cents a share.

Technically, Z forms a seven-month base and is under extreme accumulation. At this stage, the 102.20 high of 3/21 makes for a possible entrance pivot in the absence of a cheater pivot. Much depends upon the general market climate for this issue and all others in this report.

motm040614-z

Cara Therapeutics (CARA) develops pain-relief solutions. The stock vaulted more than 100% in its first four weeks as a public entity in February. As a development-stage concern, CARA has no earnings estimates and little in the way of revenue. One would be essentially “buying off the chart.” This is another we are watching to see how it responds to any firming in the averages.

motm040614-cara

In summation, pattern setups are fewer than at any time since ’12. A generous cash position is advised for the medium-term speculator in high relative-strength shares.

Kevin Marder

For intraday ideas and analysis: https://twitter.com/mardermarket

Charts created using TradeStation. ©TradeStation Technologies, 2001-2014. All rights reserved.

The views contained herein represent those of Marder Investment Advisors Corp. At the time of this writing, of the stocks mentioned in this report, Gil Morales & Company LLC (“GMC”), Marder Investment Advisors Corp., Kevin Marder, or an affiliate thereof held no positions, though positions are subject to change at any time and without notice.
Gil Morales & Company, LLC (“GMC”), 8033 Sunset Boulevard, Suite 830, Los Angeles, California, 90046. GMC is a Registered Investment Adviser. This information is issued solely for informational purposes and does not constitute an offer to sell or a solicitation of an offer to buy securities. Information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of available data. Past performance is not a guarantee, nor is it necessarily indicative, of future results. Opinions expressed herein are statements of our judgment as of the publication date and are subject to change without notice. Entities including but not limited to GMC, its members, officers, directors, employees, customers, agents, and affiliates may have a position, long or short, in the securities referred to herein, and/or other related securities, and may increase or decrease such position or take a contra position. Additional information is available upon written request. This publication is for clients of Gil Morales & Company, LLC. Reproduction without written permission is strictly prohibited and will be prosecuted to the full extent of the law. ©2008-2017 Gil Morales & Company, LLC. All rights reserved.